# US 2014/0235711 A1 · Delayed release, oral dosage compositions that contain amorphous cddo-me

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0235711 A1
- Document ID: US20140235711A1
- Status: Published application
- Kind: A1
- Application number: 14/266,031
- Filed: 2014-04-30
- Published: 2014-08-21
- Earliest claimed: 2009-02-13
- Assignees: Reata Pharmaceuticals, Inc.
- Applicants: Reata Pharmaceuticals, Inc.
- Inventors: Jiang Zhang; Colin J. MEYER
- Web page: https://patentgrep.com/patent/US20140235711A1

## CPC

- A61K 31/277: having a ring, e.g. verapamil
- A61K 9/1635: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/4866: {Organic macromolecular compounds}
- A61K 31/70: Carbohydrates; Sugars; Derivatives thereof (sorbitol A61K31/047)
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07J 63/008: {Expansion of ring D by one atom, e.g. D homo steroids}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)
- C07J: STEROIDS (seco-steroids C07C)

## Abstract

Pharmaceutical formulations exhibit a desirably low Cmax, among other properties, that contain particles of amorphous bardoxolone methyl, either in pure form or in the form of a solid dispersion, admixed with particles of a hydrophilic binding agent. Such formulations possess the advantage of higher oral bioavailability, relative to formulations based on the crystalline form of bardoxolone methyl.

## Claims

### Claim 1

A solid dosage form comprising (A) particles comprised of amorphous bardoxolone methyl admixed with (B) particles comprised of at least one hydrophilic binder, wherein said particles (A) constitute a therapeutically effective amount of bardoxolone methyl.

### Claim 2 (depends on 1)

The solid dosage form of claim 1, wherein the hydrophilic binder is a cellulose-based excipient.

### Claim 3 (depends on 1)

The solid dosage form of claim 1, wherein said particles (A) are comprised of a solid dispersion of amorphous bardoxolone methyl in a glassy matrix.

### Claim 4 (depends on 3)

The solid dosage form of claim 3, wherein said particles (A) are the product of a process that comprises spray drying a mixture of bardoxolone methyl and a methacrylic acid copolymer.

### Claim 5 (depends on 4)

The solid dosage form of claim 4, wherein said process comprises spray drying a 4:6 mixture of bardoxolone methyl and a methacrylic acid copolymer.

### Claim 6 (depends on 2)

The solid dosage form of claim 2, wherein the cellulose-based excipient is selected from the group consisting of C3-C10 alkyl hydroxymethyl cellulose, aryl hydroxymethyl cellulose, and substituted aryl hydroxymethyl cellulose.

### Claim 7 (depends on 5)

The solid dosage form of claim 5, wherein the cellulose-based excipient is a C3-C10 alkyl hydroxymethyl cellulose selected from the group consisting of methyl cellulose, ethyl cellulose, propyl cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, and cellulose acetate.

### Claim 8 (depends on 6)

A solid dosage form of claim 6, wherein the cellulose-based excipient is hydroxypropyl methyl cellulose.

### Claim 9 (depends on 1)

The solid dosage form of claim 1, wherein the hydrophilic binder is a naturally occurring carbohydrate polymer.

### Claim 10 (depends on 1)

The solid dosage form of claim 1, wherein the hydrophilic binder is an anionic polymer.

### Claim 11 (depends on 1)

The solid dosage form of claim 1, wherein said particles (A) consist essentially of amorphous bardoxolone methyl.

### Claim 12 (depends on 1)

The solid dosage form of claim 1, wherein the proportion of the hydrophilic binder is between about 1% and about 40% (w/w) of the total formulation.

### Claim 13 (depends on 12)

The solid dosage form of claim 12, wherein the proportion of the hydrophilic binder is between about 2% and about 20% (w/w) of the total formulation.

### Claim 14 (depends on 12)

The solid dosage form of claim 12, wherein the proportion of the hydrophilic binder is between about 4% and about 10% (w/w) of the total formulation.

### Claim 15 (depends on 12)

The solid dosage form of claim 12, wherein the proportion of the hydrophilic binder is between about 5% and about 7.5% (w/w) of the total formulation.

### Claim 16 (depends on 12)

The solid dosage form of claim 12, wherein the proportion of the hydrophilic binder is between about 7% and about 7.5% (w/w) of the total formulation.

### Claim 17 (depends on 12)

The solid dosage form of claim 12, wherein the proportion of the hydrophilic binder is about 7% (w/w) of the total formulation.

### Claim 18 (depends on 12, 13, 14, 15, 16, 17)

The solid dosage form of any of claims 12-17, wherein the hydrophilic binding agent is hydroxypropyl methylcellulose.
